Precigen, Inc. PGEN R2K

Healthcare · Biotechnology · United States

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Market & Price

Market Cap

$1.55B

Current Price

$4.34

High / Low (52W)

$5.21 / $1.32

Beta

1.07

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.06

Price to Book

76.14

P/S

48.97

EV/EBITDA

-18.41

Dividend Yield

Profitability & Returns

ROCE

ROE

ROA

-42.07%

Profit Margin

0.00%

Op Margin

-25.78%

EPS (Latest Qtr)

$-0.02

EPS (TTM)

$-1.21

Balance Sheet & Liquidity

Debt/Equity

4.86

Quick Ratio

3.93

Current Ratio

4.82

Debt

$98.25M

Total Assets

$155.50M

Current Assets

$115.23M

Working Capital

$77.93M

Ownership

Promoter Holding

13.78%

Chg in Prom Hold

FII / Inst Holding

71.04%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.59B

Total Revenue (TTM)

$31.59M

EBITDA

$-86.33M

Free Cash Flow

$-90.11M

Operating Cash Flow

$-115.33M

Shares Outstanding

356.51M

Gross Margin

-35.38%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-28.87%

Profit 5Y

-328.38%

Revenue (YoY)

1,633.90%

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -28.9% CAGR over 5 years.
Earnings shrank at -328.4% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PGEN Precigen, Inc. R2K	4.34	-	$1.55B	-	-	-	-28.87%	-328.38%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	46.02M	-	39.67M	45.27M	32.45M	-	22.59M	32.84M	18.30M	17.00M	29.84M	30.42M	23.58M	19.33M	24.51M	3.81M	3.33M	5.51M	2.91M	16.72M	1.85M	1.77M	-	-	-	-	-	1.34M	856.00K	2.92M	4.57M	23.25M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.10M	1.09M	1.03M	1.60M	2.56M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	241.00K	-236.00K	1.89M	2.97M	20.69M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.84M	27.62M	36.37M	24.64M	26.69M
Operating Income	-7.92M	-34.40M	-40.53M	-23.22M	-28.82M	-32.59M	-31.38M	-35.27M	-44.75M	-26.49M	-42.24M	-34.81M	-58.33M	-268.12M	-41.85M	-21.51M	-34.70M	-68.72M	-16.60M	-11.83M	-23.01M	-35.17M	-	-	-	-	-	-	-	-	-	-	-	-	-	-22.60M	-27.86M	-34.48M	-21.67M	-5.99M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-53.52M	-26.01M	-144.64M	-19.40M	-3.92M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00K	0	902.00K	2.96M	2.91M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-54.15M	-26.64M	-146.34M	-23.50M	-7.93M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3.00K	0	0	0
Net Income	-38.21M	-32.71M	-64.43M	-49.06M	-28.98M	-44.14M	-31.40M	-18.66M	-39.69M	-27.27M	-46.16M	-65.38M	-57.32M	-340.46M	-60.71M	-38.77M	-53.63M	-169.22M	-56.00M	-43.35M	-29.51M	-41.66M	-17.32M	-20.05M	-29.76M	-19.25M	-17.64M	87.38M	-22.73M	-20.32M	-19.80M	-23.74M	-58.79M	-	-	-54.15M	-26.64M	-146.34M	-23.50M	-7.93M
Diluted EPS	-0.34	-0.28	-0.55	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.35	-0.26	-0.18	-	-0.09	-0.10	-0.15	-0.10	-0.09	0.44	-0.10	-0.08	-0.08	-0.10	-0.23	-0.09	-	-0.18	-0.09	-1.06	-	-0.02
R&D Expense	21.60M	-	25.86M	28.38M	29.04M	-	34.18M	34.01M	36.47M	-	37.27M	42.05M	44.88M	-	33.06M	34.52M	31.48M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.48M	-	-	-	5.64M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	190.93M	219.46M	151.18M	90.72M	31.99M	-	26.91M	6.22M	3.92M	9.68M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	6.34M	6.12M	4.27M	4.82M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	20.57M	106.00K	-342.00K	4.86M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	95.18M	89.03M	94.36M	111.46M
Operating Income	-82.43M	-75.16M	-58.02M	-69.96M	-146.86M	-125.17M	-137.89M	-505.61M	-	-	-	-74.61M	-88.92M	-94.70M	-106.60M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-62.43M	-89.23M	-123.50M	-243.57M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	6.77M	468.00K	6.00K	3.87M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-79.97M	-96.36M	-128.03M	-250.64M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-189.00K	-458.00K	-1.79M	3.00K
Net Income	-85.28M	-81.87M	-38.98M	-81.82M	-84.49M	-186.61M	-117.02M	-509.34M	-322.32M	-170.52M	-	28.32M	-95.90M	-126.23M	-250.64M
Diluted EPS	-	-	-	-	-	-	-	-	-2.09	-1.02	-	0.14	-0.39	-0.47	-1.37
R&D Expense	70.23M	64.03M	48.14M	58.98M	147.48M	112.14M	143.21M	404.59M	-	-	-	-	48.61M	53.07M	41.33M

Compounded Sales Growth

5 Years:	-28.87%
1 Year:	1,633.90%

Compounded Profit Growth

5 Years:	-328.38%
1 Year:	-

Stock Price Performance

1 Year:	+228.79%
6 Months:	+18.26%
3 Months:	+14.51%
1 Month:	+5.34%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	151.65M	469.47M	576.27M	982.05M	949.07M	846.85M	716.18M	455.76M	314.59M	-	215.98M	151.04M	145.27M	155.50M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	118.16M	68.75M	102.41M	115.23M
Cash & Equivalents	17.37M	19.63M	10.40M	49.51M	27.47M	135.78M	62.61M	68.11M	96.88M	65.79M	51.79M	-	4.86M	7.58M	29.52M	30.23M
Inventory	-	-	-	-	-	-	-	-	-	-	-	326.00K	287.00K	-	0	9.58M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	978.00K	902.00K	926.00K	3.92M
Total Liabilities	-	-	66.54M	88.13M	166.98M	277.16M	379.82M	300.31M	337.45M	384.05M	247.41M	-	89.72M	32.55M	106.75M	134.59M
Current Liabilities	-	-	16.72M	19.83M	47.48M	75.90M	94.61M	80.17M	61.56M	122.91M	42.13M	-	78.64M	22.98M	21.52M	37.31M
Long Term Debt	-	-	-	1.65M	8.69M	7.60M	7.56M	7.54M	211.22M	186.32M	171.52M	179.88M	-	-	-	93.17M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	51.42M	7.10M	5.50M	98.29M
Total Equity	-	-	-321.55M	366.72M	384.76M	694.08M	560.24M	533.63M	362.86M	71.71M	67.17M	-	126.26M	118.50M	38.51M	20.91M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	208.15M	256.40M	292.87M	353.91M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-81.76M	-61.53M	-53.68M	-19.86M	35.67M	-48.99M	-103.72M	-124.24M	-135.93M	-77.02M	-	-65.05M	-66.93M	-68.17M	-87.83M
Investing Cash Flow	-64.10M	-23.64M	-223.66M	-26.03M	-259.25M	-28.39M	104.33M	-151.21M	86.85M	27.78M	-	226.42M	-3.09M	-20.71M	-1.53M
Financing Cash Flow	148.11M	75.94M	316.45M	24.00M	331.68M	12.06M	4.28M	309.80M	8.14M	32.70M	-	-155.29M	29.59M	110.58M	90.05M
Capital Expenditure	-13.00M	-7.49M	-1.53M	-6.37M	-12.75M	-31.63M	-46.67M	-41.59M	-37.88M	-7.53M	-	-4.92M	-1.54M	-8.58M	-2.00M
Free Cash Flow	-94.76M	-69.02M	-55.21M	-26.23M	22.92M	-80.62M	-150.39M	-165.83M	-173.81M	-84.55M	-	-69.97M	-68.47M	-76.76M	-89.83M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	6.08M	-40.43M	21.70M	682.00K

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	76.4%	1.7%	-8.7%	50.2%
Operating Margin %	-	-	-	-	-	-65.6%	-62.8%	-334.4%	-	-	-	-277.3%	-1,428.5%	-2,412.9%	-1,100.8%
Net Margin %	-	-	-	-	-	-97.7%	-53.3%	-336.9%	-355.3%	-533.0%	-	105.2%	-1,540.6%	-3,216.2%	-2,588.2%
ROE %	-	25.5%	-10.6%	-21.3%	-12.2%	-33.3%	-21.9%	-140.4%	-449.5%	-253.8%	-	22.4%	-80.9%	-327.8%	-1,198.6%
ROCE %	-	-55.7%	-12.9%	-13.2%	-16.2%	-14.6%	-18.0%	-77.2%	-	-	-	-54.3%	-69.4%	-76.5%	-90.2%

Shareholding Pattern

Insiders

13.78%

Institutions

71.04%

Public Float

82.39%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Patient Capital Management, LLC	5.00%	17.82M	$77.33M
2	Blackrock Inc.	4.27%	15.22M	$66.07M
3	State Street Corporation	3.05%	10.89M	$47.26M
4	Vanguard Capital Management LLC	2.01%	7.15M	$31.03M
5	Diametric Capital, Lp	1.91%	6.80M	$29.52M
6	Point72 Asset Management, L.P.	1.86%	6.64M	$28.84M
7	Tang Capital Management, LLC	1.80%	6.42M	$27.85M
8	Geode Capital Management, LLC	1.29%	4.61M	$20.02M
9	Occam Crest Management LP	1.20%	4.27M	$18.53M
10	Iridian Asset Management LLC	1.01%	3.59M	$15.59M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PGEN

No recent headlines available.

PGEN · Healthcare

Precigen, Inc.

About

Key Facts

Sector	Healthcare
Industry	Biotechnology
Headquarters	United States
Employees	160
Website	https://precigen.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Precigen, Inc. PGEN R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More